查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830850

2025年全球腫瘤輔助藥物市場報告

Oncology Adjuvants Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，腫瘤輔助治療市場呈現強勁成長勢頭，預計將從2024年的15.2億美元成長到2025年的16.3億美元，複合年成長率達7.6%。這段時期的成長主要受以下因素驅動：全球癌症發生率上升、對臨床前試驗可預測性要求提高、患者來源異種移植（PDX）模型應用日益廣泛、對體內療效數據依賴性增強以及對早期免疫腫瘤學研究的日益重視。

預計未來幾年腫瘤輔助藥物市場規模將維持強勁成長，2029年將達到21.7億美元，複合年成長率（CAGR）為7.3%。預測期內的成長可歸因於以下因素：對與人類相關的模型的日益關注、對精準腫瘤學需求的成長、免疫腫瘤療法的發展、對高通量篩檢模型的需求不斷成長以及對罕見癌症模型的興趣日益濃厚。這段時期的關鍵趨勢包括奈米技術的整合、用於增強CAR-T細胞療法的輔助藥物的開發、免疫腫瘤輔助藥物的進步以及人工智慧和機器學習的應用。

腫瘤輔助治療是指與癌症主要治療同時進行的藥物或療法，旨在透過增強免疫反應、降低腫瘤抗藥性和輔助症狀管理，提高癌症治療的療效、減少副作用並改善患者預後。這些治療方法的目標是為癌症治療提供更全面、更個人化的治療方法。

腫瘤輔助治療藥物主要分為化療輔助藥物、放射線治療輔助藥物、免疫治療輔助藥物、荷爾蒙療法輔助藥物、標靶治療輔助藥物。化療輔助藥物是指與第一線化療合併使用的藥物或物質，旨在提高療效、減少副作用並增強身體對癌症治療的反應。這些輔助藥物的給藥途徑多種多樣，包括口服、靜脈注射、皮下注射、局部和肌肉注射。它們適用於多種適應症，包括乳癌、神經膠母細胞瘤、肺癌、結直腸癌、卵巢癌、肉瘤和前列腺癌，並被包括癌症研究機構和專科腫瘤醫院在內的主要終端用戶廣泛使用。

2025年春季美國突然提高關稅及其引發的貿易摩擦對製藥公司造成了嚴重衝擊，這些公司正面臨原料藥、玻璃瓶和實驗室設備等產品的關稅問題。利潤率高的學名藥生產商尤其脆弱，一些公司不得不縮減低收益藥物的生產規模。生物技術公司也因關稅導致的特種試劑短缺而面臨臨床試驗延期。為了應對這一局面，製藥業正在印度和歐洲擴大原料藥的生產，增加庫存，並遊說政府對基本藥物給予貿易豁免。

這份腫瘤輔助藥物市場研究報告是商業研究公司最新發布的系列報告之一，提供腫瘤輔助藥物市場統計數據，例如全球市場規模、區域佔有率、競爭對手及其市場佔有率、市場細分、市場趨勢以及腫瘤輔助藥物行業的商機。本報告對腫瘤輔助藥物產業的現狀和未來發展趨勢進行了詳細分析，為您提供所需的一切全面資訊。

未來幾年，對個人化醫療日益成長的需求預計將推動腫瘤輔助治療市場的成長。個人化醫療根據患者的基因譜和生活方式量身定做治療方案，在提高療效的同時最大限度地減少副作用。基因和分子譜分析技術的進步使醫療服務提供者能夠根據患者腫瘤的特徵，設計特異性針對殘留癌細胞的腫瘤輔助性治療。例如，個人化醫療聯盟在2023年2月報告稱，2022年共有12種新的個人化療法核准，約佔所有新核准療法的34%，顯示個人化療法的應用顯著增加。這種對個人化醫療日益成長的關注正在推動腫瘤輔助治療市場的發展。

腫瘤輔助治療市場的企業正在推動輔助性治療免疫查核點抑制劑等療法的研發。免疫查核點抑制劑能夠阻斷PD-1、PD-L1和CTLA-4等通常抑制免疫活性的蛋白質，使T細胞能夠更有效地攻擊癌細胞。例如，默克公司於2023年1月推出了KEYTRUDA（Pembrolizumab），用於手術和含鉑類藥物輔助性治療。 化療透過抑制PD-1受體，恢復免疫系統對癌細胞的識別，從而降低復發風險，提高總存活期，並支持癌症治療的個人化方案。

2022年5月，總部位於挪威的臨床階段免疫腫瘤公司Targovax ASA與總部位於美國的Agenus Inc.達成合作，共同推動ONCOS-102黑色素瘤免疫療法臨床試驗。此次合作將雙方在腫瘤輔助治療和免疫療法領域的專業知識相結合，旨在評估ONCOS-102治療黑色素瘤的安全性和有效性，並透過創新的標靶免疫療法策略改善患者的治療效果。

腫瘤輔助治療市場由提供治療增強、副作用減少、腫瘤抗藥性預防和個人化治療最佳化等服務的營業單位所獲得的收益所構成。市場價值還包括服務提供者銷售的或包含在其服務產品中的相關產品的價值。腫瘤輔助治療市場還包括營養輔助劑、基因治療輔助劑、溶瘤病毒輔助劑和熱療輔助劑的銷售。該市場的價值為“出廠價”，即產品製造商或生產商銷售的產品價值，無論銷售對像是其他營業單位（包括下游製造商、批發商、經銷商和零售商）還是直接銷售給最終客戶。該市場的產品價值還包括產品製造商提供的任何相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅，以及新冠疫情及其復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球腫瘤輔助治療：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 終端用戶產業分析
  • 全球腫瘤輔助藥物市場：成長率分析
  • 全球腫瘤輔助治療市場表現：規模與成長，2019-2024年
  • 全球腫瘤輔助藥物市場預測：規模與成長，2024-2029年，2034年
  • 全球腫瘤輔助藥物：潛在市場規模 (TAM)

第6章 市場細分

  • 全球腫瘤輔助藥物市場（依輔助藥物類型、表現及預測分類，2019-2024年、2024-2029年、2034年）
  • 化療輔助
  • 放射輔助劑
  • 免疫療法佐劑
  • 荷爾蒙佐劑
  • 標靶治療輔助
  • 全球腫瘤輔助藥物市場依給藥途徑、效能及預測分類，2019-2024年、2024-2029年、2034年
  • 口服
  • 靜脈
  • 皮下
  • 局部的
  • 肌肉注射
  • 全球腫瘤輔助藥物市場依適應症、療效及預測分類，2019-2024年、2024-2029年、2034年
  • 乳癌
  • 神經膠母細胞瘤
  • 肺癌
  • 大腸直腸癌
  • 卵巢癌
  • 肉瘤
  • 攝護腺癌
  • 其他跡象
  • 全球腫瘤輔助藥物市場依最終用戶、效能和預測分類，2019-2024年、2024-2029年、2034年
  • 癌症研究所
  • 癌症醫院
  • 全球腫瘤輔助藥物市場：化療輔助藥物細分（按類型）、表現及預測，2019-2024年、2024-2029年、2034年
  • 烷化劑
  • 抗代謝物
  • 細胞週期蛋白
  • 植物生物鹼
  • 拓樸異構酶抑制劑
  • 鉑化合物
  • 全球腫瘤輔助治療市場：依放射輔助治療（按類型）細分、表現及預測，2019-2024年、2024-2029年、2034年
  • 放射增敏劑
  • 輻射防護器
  • 缺氧細胞敏化劑
  • 去氧核糖核酸（DNA）修復抑制劑
  • 免疫調節劑合併放射線治療
  • 全球腫瘤佐劑市場：依免疫療法佐劑（按類型）細分、效能及預測，2019-2024年、2024-2029年、2034年
  • 查核點抑制劑
  • 細胞激素
  • 癌症疫苗
  • 過繼性細胞移植
  • 免疫調節劑
  • 全球腫瘤輔助藥物市場：依荷爾蒙輔助藥物（類型）細分、效能及預測，2019-2024年、2024-2029年、2034年
  • 選擇性雌激素受體調節
  • Aromatase抑制劑
  • 促性腺激素分泌釋放激素促效劑或拮抗劑
  • 雄性激素受體抑制劑
  • 雌激素受體穩壓器
  • 全球腫瘤輔助治療市場：細分市場（標靶治療輔助藥物，按類型分類）、表現及預測（2019-2024年、2024-2029年、2034年）
  • 蛋白酪氨酸激酶抑制劑（TKI）
  • 蛋白酶體抑制劑
  • 聚（ADP-核糖）聚合酵素（PARP）抑制劑
  • mTOR抑制劑
  • v-Raf 鼠肉瘤病毒癌基因同源物 B (BRAF) 或絲裂原活化蛋白激酶激酶 (MEK) 抑制劑
  • 血管內皮生長因子（VEGF）抑制劑

第7章 區域和國家分析

  • 全球腫瘤輔助藥物市場：依地區、績效及預測分類，2019-2024年、2024-2029年、2034年
  • 全球腫瘤輔助藥物市場依國家分類、績效及預測（2019-2024 年、2024-2029 年、2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 腫瘤輔助治療市場：競爭格局
  • 腫瘤輔助治療市場：公司概況
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
    • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Novartis AG
  • Eli Lilly And Company
  • Amgen Inc.
  • Regeneron Pharmaceuticals
  • Daiichi Sankyo Company Limited
  • SEPPIC
  • Ipsen SA
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Croda International Plc
  • Dynavax Technologies Corporation
  • Agenus Inc.
  • Aurorium
  • Elicio Therapeutics Inc.

第32章 全球市場競爭基準化分析與儀錶板

第33章 重大併購

第34章 近期市場趨勢

第35章：高潛力市場國家、細分市場與策略

  • 2029年腫瘤輔助藥物市場：蘊藏新機會的國家
  • 2029年腫瘤輔助藥物市場：蘊藏新機會的細分市場
  • 2029年腫瘤輔助藥物市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章附錄

簡介目錄
Product Code: r37841

Oncology adjuvants are substances or therapies administered alongside primary cancer treatments to enhance their effectiveness, minimize side effects, and improve patient outcomes by strengthening the immune response, reducing tumor resistance, or assisting in symptom management. They aim to provide a more comprehensive and personalized approach to cancer care.

The key types of oncology adjuvants include chemotherapy adjuvants, radiation adjuvants, immunotherapy adjuvants, hormonal adjuvants, and targeted therapy adjuvants. Chemotherapy adjuvants are drugs or substances used alongside primary chemotherapy treatments to improve efficacy, reduce side effects, or enhance the body's response to cancer therapy. These adjuvants are administered via various routes, including oral, intravenous, subcutaneous, topical, and intramuscular methods. They are applied across multiple indications, such as breast cancer, glioblastoma, lung cancer, colorectal cancer, ovarian cancer, sarcoma, prostate cancer, and others, and are utilized by key end users including cancer research institutes and specialized cancer hospitals.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The oncology adjuvants market research report is one of a series of new reports from The Business Research Company that provides oncology adjuvants market statistics, including oncology adjuvants industry global market size, regional shares, competitors with an oncology adjuvants market share, oncology adjuvants market segments, market trends and opportunities, and any further data you may need to thrive in the oncology adjuvants industry. This oncology adjuvants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology adjuvants market size has grown strongly in recent years. It will grow from $1.52 billion in 2024 to $1.63 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to the rising incidence of cancer worldwide, increasing demand for improved preclinical predictability, growing utilization of patient-derived xenograft (PDX) models, expanding reliance on in vivo efficacy data, and heightened focus on early-stage immuno-oncology research.

The oncology adjuvants market size is expected to see strong growth in the next few years. It will grow to $2.17 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to the increasing focus on human-relevant models, rising demand for precision oncology, growth in immuno-oncology treatments, increasing need for high-throughput screening models, and expanding interest in rare cancer models. Key trends during this period include the integration of nanotechnology, development of adjuvants enhancing CAR-T cell therapies, advancements in immuno-oncology adjuvants, and the application of artificial intelligence and machine learning.

The increasing demand for personalized medicine is expected to drive the growth of the oncology adjuvants market in the coming years. Personalized medicine tailors treatments based on a patient's genetic profile and lifestyle, improving treatment efficacy while minimizing adverse effects. Advances in genetic and molecular profiling allow healthcare providers to design oncology adjuvant therapies that specifically target residual cancer cells according to the patient's tumor characteristics. For instance, in February 2023, the Personalized Medicine Coalition reported that 12 new personalized medicines approved in 2022 accounted for approximately 34% of all newly approved therapies, demonstrating a notable increase in adoption. This rising focus on individualized treatment is fueling the oncology adjuvants market.

Companies in the oncology adjuvants market are advancing therapies such as immune checkpoint inhibitor adjuvant treatments, which enhance post-surgical outcomes by leveraging the patient's immune system to target remaining tumor cells. Immune checkpoint inhibitors block proteins like PD-1, PD-L1, or CTLA-4 that normally suppress immune activity, thereby allowing T-cells to attack cancer more effectively. For example, in January 2023, Merck & Co., Inc., launched KEYTRUDA (pembrolizumab) as an adjuvant therapy for Stage IB (T2a >=4 cm), II, or IIIA non-small cell lung cancer (NSCLC) following surgery and platinum-based chemotherapy. By blocking the PD-1 receptor, KEYTRUDA restores immune detection of cancer cells, reducing recurrence risk and improving overall survival, while supporting a personalized approach to cancer care.

In May 2022, Targovax ASA, a Norway-based clinical-stage immuno-oncology company, collaborated with US-based Agenus Inc. to advance the ONCOS-102 melanoma immunotherapy trial. This partnership combines expertise in oncology adjuvants and immunotherapy to evaluate ONCOS-102's safety and efficacy in melanoma treatment, aiming to improve patient outcomes through innovative, targeted immunotherapy strategies.

Major players in the oncology adjuvants market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, SEPPIC, Ipsen S.A., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Aurorium, Elicio Therapeutics Inc.

North America was the largest region in the oncology adjuvants market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncology adjuvants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oncology adjuvants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oncology adjuvants market consists of revenues earned by entities by providing services such as treatment enhancement, side effect reduction, tumor resistance prevention, and personalized therapy optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncology adjuvants market also includes sales of nutritional adjuvants, gene therapy adjuvants, oncolytic virus adjuvants, and hyperthermia adjuvants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Adjuvants Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology adjuvants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology adjuvants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology adjuvants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type Of Adjuvant: Chemotherapy Adjuvants; Radiation Adjuvants; Immunotherapy Adjuvants; Hormonal Adjuvants; Targeted Therapy Adjuvants
  • 2) By Administration Route: Oral; Intravenous; Subcutaneous; Topical; Intramuscular
  • 3) By Indication: Breast Cancer; Glioblastoma; Lung Cancer; Colorectal Cancer; Ovarian Cancer; Sarcoma; Prostate Cancer; Other Indications
  • 4) By End User: Cancer Research Institute; Cancer Hospitals
  • Subsegments:
  • 1) By Chemotherapy Adjuvants: Alkylating Agents; Antimetabolites; Anthracyclines; Plant Alkaloids; Topoisomerase Inhibitors; Platinum-Based Compounds; Others
  • 2) By Radiation Adjuvants: Radiosensitizers; Radioprotectors; Hypoxic Cell Sensitizers; Deoxyribonucleic Acid (DNA) Repair Inhibitors; Immune Modulating Agents Combined With Radiation
  • 3) By Immunotherapy Adjuvants: Checkpoint Inhibitors; Cytokines; Cancer Vaccines; Adoptive Cell Transfer; Immune Modulating Agents
  • 4) By Hormonal Adjuvants: Selective Estrogen Receptor Modulators; Aromatase Inhibitors; Gonadotropin-Releasing Hormone Agonists Or Antagonists; Androgen Receptor Inhibitors; Estrogen Receptor Downregulators
  • 5) By Targeted Therapy Adjuvants: Tyrosine Kinase Inhibitors (TKIs); Proteasome Inhibitors; Poly (ADP-Ribose) Polymerase (PARP) Inhibitors; mTOR Inhibitors; v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors; Vascular Endothelial Growth Factor (VEGF) Inhibitors
  • Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Roche Holding AG; Merck And Co. Inc.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; Eli Lilly And Company; Amgen Inc.; Regeneron Pharmaceuticals; Daiichi Sankyo Company Limited; SEPPIC; Ipsen S.A.; Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Croda International Plc; Dynavax Technologies Corporation; Agenus Inc.; Aurorium; Elicio Therapeutics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncology Adjuvants Market Characteristics

3. Oncology Adjuvants Market Trends And Strategies

4. Oncology Adjuvants Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Oncology Adjuvants Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Oncology Adjuvants PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Oncology Adjuvants Market Growth Rate Analysis
  • 5.4. Global Oncology Adjuvants Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Oncology Adjuvants Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Oncology Adjuvants Total Addressable Market (TAM)

6. Oncology Adjuvants Market Segmentation

  • 6.1. Global Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chemotherapy Adjuvants
  • Radiation Adjuvants
  • Immunotherapy Adjuvants
  • Hormonal Adjuvants
  • Targeted Therapy Adjuvants
  • 6.2. Global Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Intravenous
  • Subcutaneous
  • Topical
  • Intramuscular
  • 6.3. Global Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Breast Cancer
  • Glioblastoma
  • Lung Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Sarcoma
  • Prostate Cancer
  • Other Indications
  • 6.4. Global Oncology Adjuvants Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cancer Research Institute
  • Cancer Hospitals
  • 6.5. Global Oncology Adjuvants Market, Sub-Segmentation Of Chemotherapy Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alkylating Agents
  • Antimetabolites
  • Anthracyclines
  • Plant Alkaloids
  • Topoisomerase Inhibitors
  • Platinum-Based Compounds
  • 6.6. Global Oncology Adjuvants Market, Sub-Segmentation Of Radiation Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Radiosensitizers
  • Radioprotectors
  • Hypoxic Cell Sensitizers
  • Deoxyribonucleic Acid (DNA) Repair Inhibitors
  • Immune Modulating Agents Combined With Radiation
  • 6.7. Global Oncology Adjuvants Market, Sub-Segmentation Of Immunotherapy Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Checkpoint Inhibitors
  • Cytokines
  • Cancer Vaccines
  • Adoptive Cell Transfer
  • Immune Modulating Agents
  • 6.8. Global Oncology Adjuvants Market, Sub-Segmentation Of Hormonal Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Selective Estrogen Receptor Modulators
  • Aromatase Inhibitors
  • Gonadotropin-Releasing Hormone Agonists Or Antagonists
  • Androgen Receptor Inhibitors
  • Estrogen Receptor Downregulators
  • 6.9. Global Oncology Adjuvants Market, Sub-Segmentation Of Targeted Therapy Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tyrosine Kinase Inhibitors (TKIs)
  • Proteasome Inhibitors
  • Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
  • mTOR Inhibitors
  • v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors
  • Vascular Endothelial Growth Factor (VEGF) Inhibitors

7. Oncology Adjuvants Market Regional And Country Analysis

  • 7.1. Global Oncology Adjuvants Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Oncology Adjuvants Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Adjuvants Market

  • 8.1. Asia-Pacific Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Adjuvants Market

  • 9.1. China Oncology Adjuvants Market Overview
  • 9.2. China Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Adjuvants Market

  • 10.1. India Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Adjuvants Market

  • 11.1. Japan Oncology Adjuvants Market Overview
  • 11.2. Japan Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Adjuvants Market

  • 12.1. Australia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Adjuvants Market

  • 13.1. Indonesia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Adjuvants Market

  • 14.1. South Korea Oncology Adjuvants Market Overview
  • 14.2. South Korea Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Adjuvants Market

  • 15.1. Western Europe Oncology Adjuvants Market Overview
  • 15.2. Western Europe Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Adjuvants Market

  • 16.1. UK Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Adjuvants Market

  • 17.1. Germany Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Adjuvants Market

  • 18.1. France Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Adjuvants Market

  • 19.1. Italy Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Adjuvants Market

  • 20.1. Spain Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Adjuvants Market

  • 21.1. Eastern Europe Oncology Adjuvants Market Overview
  • 21.2. Eastern Europe Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Adjuvants Market

  • 22.1. Russia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Adjuvants Market

  • 23.1. North America Oncology Adjuvants Market Overview
  • 23.2. North America Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Adjuvants Market

  • 24.1. USA Oncology Adjuvants Market Overview
  • 24.2. USA Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Adjuvants Market

  • 25.1. Canada Oncology Adjuvants Market Overview
  • 25.2. Canada Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Adjuvants Market

  • 26.1. South America Oncology Adjuvants Market Overview
  • 26.2. South America Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Adjuvants Market

  • 27.1. Brazil Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Adjuvants Market

  • 28.1. Middle East Oncology Adjuvants Market Overview
  • 28.2. Middle East Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Adjuvants Market

  • 29.1. Africa Oncology Adjuvants Market Overview
  • 29.2. Africa Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Adjuvants Market Competitive Landscape And Company Profiles

  • 30.1. Oncology Adjuvants Market Competitive Landscape
  • 30.2. Oncology Adjuvants Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Adjuvants Market Other Major And Innovative Companies

  • 31.1. Bristol-Myers Squibb Company
  • 31.2. AstraZeneca PLC
  • 31.3. Novartis AG
  • 31.4. Eli Lilly And Company
  • 31.5. Amgen Inc.
  • 31.6. Regeneron Pharmaceuticals
  • 31.7. Daiichi Sankyo Company Limited
  • 31.8. SEPPIC
  • 31.9. Ipsen S.A.
  • 31.10. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • 31.11. Croda International Plc
  • 31.12. Dynavax Technologies Corporation
  • 31.13. Agenus Inc.
  • 31.14. Aurorium
  • 31.15. Elicio Therapeutics Inc.

32. Global Oncology Adjuvants Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Adjuvants Market

34. Recent Developments In The Oncology Adjuvants Market

35. Oncology Adjuvants Market High Potential Countries, Segments and Strategies

  • 35.1 Oncology Adjuvants Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Oncology Adjuvants Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Oncology Adjuvants Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer